

Roland Klingenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6093080/publications.pdf>

Version: 2024-02-01

45
papers

1,947
citations

361045

20
h-index

253896

43
g-index

45
all docs

45
docs citations

45
times ranked

4288
citing authors

#	ARTICLE	IF	CITATIONS
1	Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome. <i>Nicotine and Tobacco Research</i> , 2023, 25, 58-65.	1.4	2
2	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. <i>American Heart Journal</i> , 2022, 247, 33-41.	1.2	8
3	Rapid Inflammasome Activation Is Attenuated in Post-Myocardial Infarction Monocytes. <i>Frontiers in Immunology</i> , 2022, 13, 857455.	2.2	3
4	Extracellular vesicle species differentially affect endothelial cell functions and differentially respond to exercise training in patients with chronic coronary syndromes. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1467-1474.	0.8	11
5	Prognostic value of total testosterone levels in patients with acute coronary syndromes. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 235-242.	0.8	7
6	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 59-65.	0.8	30
7	Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 445-452.	0.4	5
8	Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. <i>Atherosclerosis</i> , 2021, 320, 31-37.	0.4	7
9	Improving 1-year mortality prediction in ACS patients using machine learning. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 855-865.	0.4	9
10	Cysteine-Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute Coronary Events) Risk Stratification. <i>Overlock 1 Heart Association</i> , 2021, 10, e020488.	1.6	4
11	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 589-598.	0.4	7
12	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. <i>International Journal of Cardiology</i> , 2020, 299, 289-295.	0.8	1
13	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. <i>International Journal of Cardiology</i> , 2020, 303, 8-13.	0.8	5
14	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1002.	1.0	11
15	Risk stratification of elderly patients with acute pulmonary embolism. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13154.	1.7	3
16	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. <i>PLoS ONE</i> , 2019, 14, e0211464.	1.1	6
17	Inflammation during acute coronary syndromes – Risk of cardiovascular events and bleeding. <i>International Journal of Cardiology</i> , 2019, 287, 13-18.	0.8	22
18	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13117.	1.7	24

#	ARTICLE	IF	CITATIONS
19	Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 16-24.	0.7	3
20	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	11
21	Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. <i>Cardiovascular Research</i> , 2018, 114, 1178-1188.	1.8	44
22	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 129-138.	0.4	70
23	Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 522-531.	0.4	7
24	Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. <i>PLoS ONE</i> , 2018, 13, e0195174.	1.1	21
25	Prognostic value of pulse pressure after an acute coronary syndrome. <i>Atherosclerosis</i> , 2018, 277, 219-226.	0.4	15
26	Predictive value of the age, creatinine, and ejection fraction (ACEF) score in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2018, 270, 7-13.	0.8	33
27	Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2017, 38, ehw563.	1.0	77
28	Increased Proangiogenic Activity of Mobilized CD34 ⁺ Progenitor Cells of Patients With Acute ST-Segmentâ€Elevation Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 341-349.	1.1	40
29	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. <i>European Heart Journal</i> , 2017, 38, ehw582.	1.0	317
30	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	29
31	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. <i>European Heart Journal</i> , 2017, 38, 3493-3502.	1.0	46
32	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. <i>European Heart Journal</i> , 2016, 37, 1967-1976.	1.0	433
33	Decreased phosphatidylcholine plasmalogens â€A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. <i>Atherosclerosis</i> , 2016, 246, 130-140.	0.4	47
34	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2016, 37, 546-553.	1.0	120
35	Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy. <i>Atherosclerosis</i> , 2016, 247, 154-160.	0.4	22
36	Low statin use in adults hospitalized with acute coronary syndrome. <i>Preventive Medicine</i> , 2015, 77, 131-136.	1.6	18

#	ARTICLE	IF	CITATIONS
37	Acute rupture of a thin cap fibroatheroma: value of multimodality imaging. <i>European Heart Journal</i> , 2015, 36, 1001-1001.	1.0	1
38	Circulating FABP4 Is a Prognostic Biomarker in Patients With Acute Coronary Syndrome but Not in Asymptomatic Individuals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1872-1879.	1.1	36
39	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. <i>European Heart Journal</i> , 2015, 36, 2438-2445.	1.0	129
40	Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. <i>Heart</i> , 2015, 101, 854-863.	1.2	38
41	Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes. <i>European Heart Journal</i> , 2015, 36, 1041-1048.	1.0	48
42	Quality of Care after Acute Coronary Syndromes in a Prospective Cohort with Reasons for Non-Prescription of Recommended Medications. <i>PLoS ONE</i> , 2014, 9, e93147.	1.1	28
43	High-sensitivity Troponins – “Difficult Friends in Acute Coronary Syndromes. <i>US Cardiology Review</i> , 2012, 9, 121-125.	0.5	0
44	Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. <i>European Heart Journal</i> , 2009, 30, 2838-2844.	1.0	149
45	Coronary stent thrombosis in acute coronary syndromes. <i>Cardiovascular Medicine(Switzerland)</i> , 0, , .	0.1	0